Progyny (PGNY) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Progyny (NASDAQ: PGNY) recently:

• 8/12/2026 – Progyny had its price target lowered by Barclays PLC from $34.00 to $30.00. They now have an “equal weight” rating on the stock.
• 8/7/2026 – Progyny was given a new $35.00 price target by Canaccord Genuity Group Inc..
• 7/28/2026 – Progyny had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $34.00 price target on the stock, up from $27.00.
• 7/28/2026 – Progyny had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $34.00 price target on the stock, up from $27.00.
• 7/25/2026 – Progyny was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/24/2026 – Progyny had its price target raised by BTIG Research from $30.00 to $40.00. They now have a “buy” rating on the stock.
• 7/22/2026 – Progyny was given a new $38.00 price target by Leerink Partners.
• 7/21/2026 – Progyny had its price target raised by Canaccord Genuity Group Inc. from $30.00 to $36.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Progyny had its price target raised by KeyCorp from $30.00 to $35.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Progyny was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/27/2026 – Progyny was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/26/2026 – Progyny was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 6/22/2026 – Progyny had its price target raised by Truist Financial Corporation from $30.00 to $33.00. They now have a “buy” rating on the stock.

Insider Activity

In other Progyny news, COO Melissa B. Cummings sold 9,578 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the sale, the chief operating officer owned 73,371 shares in the company, valued at approximately $1,834,275. This represents a 11.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total value of $39,137.40. Following the completion of the sale, the insider directly owned 59,117 shares of the company’s stock, valued at $1,512,212.86. This trade represents a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,916 shares of company stock valued at $939,875 in the last ninety days. 9.90% of the stock is currently owned by corporate insiders.

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.